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Ursodeoxycholic Acid Protects Against Secondary
Biliary Cirrhosis in Rats by Preventing Mitochondrial
Oxidative Stress
Gaetano Serviddio,1,2 Javier Pereda,2 Federico V. Pallardo´,2 Julian Carretero,2 Consuelo Borras,2 Juan Cutrin,3
Gianluigi Vendemiale,1 Giuseppe Poli,3 Jose´ Vin˜a,2 and Juan Sastre2
Ursodeoxycholic acid (UDCA) improves clinical and biochemical indices in primary biliary
cirrhosis and prolongs survival free of liver transplantation. Recently, it was suggested that the
cytoprotective mechanisms of UDCA may be mediated by protection against oxidative stress,
which is involved in the development of cirrhosis induced by chronic cholestasis. The aims of the
current study were 1) to identify the mechanisms involved in glutathione depletion, oxidative
stress, and mitochondrial impairment during biliary cirrhosis induced by chronic cholestasis in
rats; and 2) to determine themechanisms associated with the protective effects of UDCA against
secondary biliary cirrhosis. The findings of the current study indicate that UDCA partially
prevents hepatic and mitochondrial glutathione depletion and oxidation resulting from chronic
cholestasis. Impairment of biliary excretion was accompanied by decreased steady-state hepatic
levels of -glutamyl cysteine synthetase and -cystathionase messenger RNAs. UDCA treatment
led to up-regulation of-glutamyl cysteine synthetase in animalswith secondary biliary cirrhosis
andprevented themarked increases inmitochondrial peroxide production andhydroxynonenal-
protein adduct production that are observed during chronic cholestasis. A population of dam-
aged and primarily apoptotic hepatocytes characterized by dramatic decreases in mitochondrial
cardiolipin levels and membrane potential as well as phosphatidylserine exposure evolves in
secondary biliary cirrhosis. UDCA treatment prevents the growth of this population along with
the decreases in mitochondrial cardiolipin levels and membrane potential that are induced by
chronic cholestasis. In conclusion, UDCA treatment enhances the antioxidant defense mediated
by glutathione; in doing so, this treatment prevents cardiolipin depletion and cell injury in
animals with secondary biliary cirrhosis. (HEPATOLOGY 2004;39:711–720.)
Cholestasis occurs in numerous chronic humandiseases including primary biliary cirrhosis(PBC), primary sclerosing cholangitis, allograft
rejection, iatrogenic obstruction of bile ducts, and biliary
atresia.1 Elucidation of the cellular and molecular mech-
anisms that lead to liver injury and fibrosis is critical in
designing new interventional strategies for treating these
disorders. Although the primary injury to the bile ducts
may be immunologic, toxic, or genetic, progression of
liver disease appears to be promoted by secondary chem-
ical damage to hepatocytes as a result of toxic hydrophobic
bile salts.2,3 Cholestasis results in intrahepatic accumulation
of potentially toxic bile acids, and this accumulation leads to
hepatocyte apoptosis, necrosis, and, eventually, biliary fibro-
sis and cirrhosis.4 In vitro exposure to high concentrations of
hydrophobic bile acids has been linked to necrosis in freshly
isolated hepatocytes and primary cultured hepatocytes5,6;
this association explains the observation of cellular swelling,
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disrupted plasmamembrane integrity, and cytosolic enzyme
release in cholestasis.7
Oxidative stress plays an important role in cell death8,9
and has been linked to the development of cholestatic
liver injury. Hydrophobic bile acids stimulate the gener-
ation of reactive oxygen species (ROS) in hepatocytes5,10
and in livermitochondria.5,11 Evidence of oxidative injury
has been found in rats receiving intravenously infused
hydrophobic bile acids12 and in the bile duct–ligated rat
model of cholestasis.13,14 Recently, Sokol et al.12 proposed
that hydrophobic bile acids accumulate intracellularly
during cholestasis and interfere with normal mitochon-
drial electron transport, inhibiting the activity of respira-
tory complexes I and III and consequently reducing
adenosine triphosphate synthesis.15 Mitochondrial dys-
function is widely recognized as a key mechanism leading
to apoptosis,16 particularly through the mitochondrial per-
meability transition (MPT). Toxic bile salts can induce the
opening ofMPTpores, and inhibition ofMPTprevents bile
salt–induced hepatocyte cytotoxicity.17,18
Administration of ursodeoxycholic acid (UDCA) is
the currently accepted method for treating cholestasis.19
Combined analysis of the three largest randomized clini-
cal trials of UDCA for PBC20 indicated that UDCA im-
proved clinical and biochemical indices and prolonged
survival free of liver transplantation. Nonetheless, the cy-
toprotective mechanisms by which UDCA acts remain
unclear. Experimental evidence suggests three primary
mechanisms of action: protection against the cytotoxicity
of hydrophobic bile acids,21 stimulation of hepatobiliary
secretion,22 and protection of hepatocytes against bile
acid–induced apoptosis.23 Recently, UDCA was shown
to have in vitro antioxidant activity in hepatocytes.24 Pre-
treatment with UDCA prevented hydrogen peroxide–in-
duced injury by increasing -glutamylcysteine synthetase
messenger RNA (mRNA) levels and, consequently, levels
of reduced glutathione (GSH).24 Furthermore, GSH lev-
els were higher in liver specimens perfused with UDCA
than in those perfused with taurocholic acid. This effect is
correlated with an increase in methionine S-adenosyl
transferase activity.25
The aims of the current study were 1) to identify the
mechanisms involved in GSH depletion, oxidative stress,
and mitochondrial impairment during biliary cirrhosis
induced by chronic cholestasis; and 2) to determine the
mechanisms associated with the protective effect of
UDCA against secondary biliary cirrhosis.
Materials and Methods
Animal Experiments. Adult male Wistar rats weigh-
ing 220–260 g were held in cages in groups of 2, fed ad
libitum, and given free access to water. All rats received
humane care according to the criteria outlined in the
Guide for the Care and Use of Laboratory Animals.26 The
study was approved by the Research Committee of the
University of Valencia School of Medicine (Valencia,
Spain). Animals were randomly divided into three
groups: a group that underwent sham operation, a group
that underwent bile duct ligation (BDL), and a group that
underwent BDL and treatment with UDCA (BDL 
UDCA). BDL was performed using a modified version of
the method described by Kountouras et al.27 Anesthesia
was induced with ketamine (100mg/kg body weight) and
acepromazine (2.5 mg/kg body weight) administered in-
traperitoneally. The peritoneal cavity was opened and the
common bile duct exposed via a right paramedian inci-
sion measuring 1.5 cm in length. BDL was achieved as
follows: the common bile duct was clamped with a surgi-
cal microclamp, ligated twice (silk suture, 5/0), and cut
through between the ligations. Control animals under-
went a sham operation that consisted of exposure of the
common bile duct without ligation. The sham operation
and BDL groups received standard nourishment, and the
BDL  UDCA group received the same nourishment
supplemented with 2.5 g/kg UDCA (Mucedola, Milan,
Italy). Food intake and body weight were monitored
throughout the 28-day experimental period.
Animals were sacrificed under anesthesia and rapidly
had their livers removed 21 or 28 days after surgery. De-
velopment of biliary cirrhosis was confirmed by histo-
chemical methods, using staining for reticulin (Fig. 1).
Histologic analysis of reticulin via the silver nitrate tech-
nique was performed with a commercial kit (D.D.K. Ita-
lia, Milan, Italy).
Fig. 1. Histochemical analysis of rat liver specimen, with staining for
reticulin after 21 days of chronic cholestasis. Original magnification
100.
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Measurement of Peroxide Production in Liver Mi-
tochondria. Liver mitochondria were isolated as de-
scribed previously.28 The rate of peroxide production in
liver mitochondria also was determined according to the
method described by Min˜ana et al.,28 which was a modi-
fied version of the method described by Barja.29
Isolation and Incubation of Hepatocytes. Hepato-
cytes were isolated from rats that had fasted for 48 hours,
as described by Romero andVin˜a.30 Cells (10–15mg [dry
weight] per mL) were incubated in Krebs–Henseleit bi-
carbonate buffer containing 5 mM glutamine (Gln), 2
mM glycine (Gly), 1 mM serine (Ser), and 0.5 mM me-
thionine (Met) or containing 5 mM Gln and 2 mM Gly
plus 0.5 mM N-acetylcysteine (NAC). A gas atmosphere
of O2 and CO2 (O2:CO2 ratio, 19:1) was used. GSH
levels weremeasured spectrophotometrically, as described
by Min˜ana et al.28
Flow Cytometric Analysis. Flow cytometric analysis
was performed using an EPICS ELITE cell sorter
(Coulter Electronics, Miami, FL). Fluorochromes were
excited with an argon laser tuned to 488 nm. Forward-
angle and right-angle light scattering were measured.
Samples were acquired for 20,000 individual cells. Mito-
chondrial membrane potential was measured using the
fluorescent dye Rhodamine-12331 at 525 5 nm fluores-
cence emission. This potential is the driving force for
Rhodamine-123 uptake. Mitochondrial cardiolipin con-
tent was measured with nonylacridine orange (final con-
centration, 10 g/mL; 525  5 nm fluorescence
emission32), which binds to mitochondrial membranes re-
gardless of their membrane potential. Therefore, mitochon-
drial uptake of this metachromatic dye does not depend on
mitochondrial energy status.33 Phosphatidylserine exposure
was measured with annexin V (Alexa Fluor 488 conjugate;
Molecular Probes, Eugene, OR) and used as an index of
apoptosis.
Cell viability was determined using the fluorescent dye
propidium iodide (final concentration, 5 g/mL) at 630
nm fluorescence emission. There were no statistical dif-
ferences in the viability of hepatocytes among the differ-
ent treatment groups. The percentage of viable
hepatocytes was 94  2.1% in the control group, 87 
4.8% in the BDL group, and 90  3.8% in the BDL 
UDCA group.
RNA Extraction and the Real-Time Polymerase
Chain Reaction (PCR). Liver tissue stored at 80 °C
was homogenized (Ultra-Turrax disperser; Janke and
Kunfel, Staufen, Germany), and total RNA was isolated
using the RNeasy kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s instructions. A PCRmaster mix
containing the specific primers (-glutamyl cysteine syn-
thetase [GCS] heavy subunit: forward, 5-ATC CTC
CAG TTC CTG CAC ATC TAC-3; reverse, 5-GAT
CGA AGG ACA CCA ACA TGT ACT C-3; -GCS
light subunit: forward, 5-TGG AGT TGC ACA GCT
GGACTCT-3; reverse, 5-CCAGTAAGGCTGTAA
ATG CTC CAA-3; cystathionase: forward, 5-TTT
CCT GGA GTC TAA TCC CCG-3; reverse, 5-TTG
AGG AAG ACC TGA GCA TGC-3; glyceraldehyde-3-
phosphate dehydrogenase (GAPDH): forward, 5-CCT
GGA GAA ACC TGC CAA GTA TG-3; reverse, 5-
GGT CCT CAG TGT AGC CCA AGA TG-3) then
was added, along with AmpliTaq Gold DNA polymerase
(Applied Biosystems; Foster City, CA). Real-time quan-
titation of -GCS heavy subunit mRNA, -GCS light
subunit mRNA, and cystathionase mRNA relative to
GAPDH mRNA was performed using SYBR Green I
(Molecular Probes, Eugene, OR), and mRNA levels were
evaluated using the iCycler detection system (Biorad,
Hercules, CA). The threshold cycle (CT) was determined,
and relative gene expression levels subsequently were calcu-
lated as follows: fold change  2(CT), where CT 
CTtarget  CThousekeeping, and ( CT)  CTtreated 
CTcontrol.
Immunohistochemistry for 4-Hydroxynonenal (HNE)-
Protein Adducts. HNE-protein adducts were detected
in 4% formalin-fixed, paraffin-embedded sections. Sec-
tions measuring 5 m in thickness were incubated with
an anti-HNE-histidine rabbit polyclonal antibody (Alpha
Diagnostic International, San Antonio, TX). Peroxidase-
linked secondary antibody and diaminobenzidine were
used to detect specific binding. No positive staining was
detected when tissue from experimental liver samples was
processed without primary antibody; this finding indi-
cated the absence of nonspecific binding under the con-
ditions used in the current study.
Assays. Mitochondrial and liver homogenate levels of
GSH and oxidized glutathione (GSSG) were measured as
described previously.28 Western blot analysis was per-
formed using the Phototope-HRP Western blot kit (Cell
Signalling, Beverly, MA) and a specific rabbit antibody
against the heavy subunit of -GCS (NeoMarkers, Fre-
mont, CA). Total protein concentration was determined
using the Lowry micromethod kit (Sigma-Aldrich, St.
Louis, MO).
Statistical Analysis. Data were expressed as mean val-
ues  standard deviations of the mean (SDM). Because
the data were not paired, differences between means were
analyzed using one-way ANOVA after Gaussian distribu-
tion evaluation with the Kolgomorov–Smirnov test. The
Tukey multiple comparisons test for all pairs of columns
was applied as a post-test. In all instances, P  .05 was
taken as an indication of significance. A commercial soft-
HEPATOLOGY, Vol. 39, No. 3, 2004 SERVIDDIO ET AL. 713
ware package (GraphPad Prism Software, SanDiego, CA)
was used to perform all statistical analyses.
Results
Prevention of Increased Mitochondrial Peroxide
Production by UDCA Treatment. Mitochondrial per-
oxide production, which may be a major contributor to
both mitochondrial and intracellular oxidative stress, was
assessed in animals with secondary biliary cirrhosis. Per-
oxide production by liver mitochondria was measured
using pyruvate and malate as complex I–linked substrates
and using succinate as a complex II–linked substrate. The
rate of peroxide production in liver mitochondria 21 days
after the induction of cholestasis was twice as great as it
was in sham-operated rats for both complex I–linked and
complex II–linked substrates (P  .01; Fig. 2). Peroxide
production increased further, to a level 3.5 times greater
than in sham-operated rats, at 28 days after BDL (P 
.001; Fig. 2). UDCA treatment completely prevented the
increase that would have been induced by cholestasis at 21
days (P  .05). The rate of peroxide production in liver
mitochondria from animals that received BDL and were
treated with UDCA for 28 days was significantly lower
than the corresponding rate in untreated rats, although it
was greater than the corresponding rate in control animals
(P  .01 for the comparison with control animals).
Partial Prevention of Hepatic and Mitochondrial
Glutathione Depletion and Oxidation During
Chronic Cholestasis by UDCA. GSH and GSSG levels
were measured in liver tissue and in hepatic mitochondria
from rats in the sham, BDL, and BDLUDCA groups.
Hepatic GSH levels (in mol per gram of liver tissue)
were significantly lower in BDL group rats comparedwith
sham-operated rats at 21 and 28 days after the induction
of cholestasis (P  .001 at 21 and 28 days; Fig. 3A);
UDCA treatment partially reversed this effect. Further-
more, GSSG levels were significantly higher in BDL
group rats than in sham-operated rats (P .001 at 21 and
28 days; Fig. 3B); this effect also was partially reversed by
UDCA treatment.
The same changes noted in hepatic glutathione levels
also were observed when mitochondrial GSH and GSSG
levels were measured. Specifically, BDL caused a signifi-
cant decrease in GSH levels and an increase in GSSG
levels. These changes also were prevented byUDCA treat-
ment (Fig. 4).
Effect of UDCA Administration on Cholestasis-In-
duced Impairment of GSH Synthesis due to Decreased
Expression of -GCS and -Cystathionase. To eluci-
date the mechanisms responsible for GSH depletion dur-
Fig. 2. Peroxide production by rat liver mitochondria during secondary
cirrhosis: protective effects of UDCA treatment. (A) Rate of peroxide
production in mitochondria incubated with 5 mM pyruvate plus 2.5 mM
malate. (B) Rate of peroxide production in mitochondria incubated with
10 mM succinate. Liver mitochondria were isolated from control group
rats, BDL group rats, and UDCA  BDL group rats after 21 and 28 days
of chronic cholestasis. Four to eight experiments were performed in each
case. Statistical differences were assessed using ANOVA and Tukey–
Kramer multicomparison tests.
Fig. 3. Effects of chronic cholestasis and UDCA treatment on hepatic
glutathione redox status. (A) GSH and (B) GSSG levels in liver homog-
enates from control group rats, BDL group rats, and UDCA  BDL group
rats after 21 and 28 days of chronic cholestasis. Five to eight experi-
ments were performed in each case. Statistical differences were as-
sessed using ANOVA and Tukey–Kramer multicomparison tests.
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ing chronic cholestasis, GSH synthesis was examined in
hepatocytes isolated from rats that had fasted for 48 hours
and were distributed into three treatment groups (sham
operation, BDL, and BDL  UDCA). GSH synthesis
was measured using two sets of substrates: 1) 5 mM Gln,
2 mM Gly, 1 mM Ser, and 0.5 mM Met; and 2) 5 mM
Gln and 2 mM Gly plus 0.5 mM NAC. For both sub-
strates, the rate of GSH synthesis was diminished in hepa-
tocytes from BDL group rats compared with sham-
operated rats (Fig. 5). UDCA treatment prevented the
decrease in the rate of GSH synthesis from the Gln 
Gly  NAC substrates, but not from the Gln  Gly 
SerMet substrates.
In the liver, the major rate-limiting factors with respect
to GSH synthesis are the activity of -cystathionase,
which determines cysteine availability, and the activity of
-GCS, which has regulatory (light [30 kd]) and catalytic
(heavy [73 kd]) subunits.34–36 Synthesis of GSH from Ser
and Met involves -cystathionase and -GCS, whereas
synthesis of GSH from NAC depends only on -GCS.
Therefore, subsequent experiments were conducted to
determine whether UDCA influenced the expression of
these enzymes’ mRNAs in the liver during chronic cho-
lestasis.
BDL led to decreased expression of themRNAs encod-
ing -GCS (both the catalytic and regulatory subunits;
P  .01; Fig. 6A,C) and -cystathionase (P  .01; Fig.
6D). UDCA prevented the decrease in expression of the
mRNAs encoding -GCS (P  .01 and P  .05 for the
catalytic and regulatory subunits, respectively; Fig. 6A,C),
but not the decrease in -cystathionase mRNA expres-
sion. UDCA also protected against the decrease, observed
in BDL group rats, in expression of the -GCS heavy
subunit at the protein level (Fig. 6B).
HNE-Protein Adducts in Secondary Biliary Cirrho-
sis. HNE-protein adduct levels have been measured by
immunohistochemical methods as an index of oxidative
damage to proteins in secondary biliary cirrhosis induced
by chronic cholestasis. Figure 7B shows the presence of
HNE-protein adducts in rat liver samples 21 days after
the induction of cholestasis. The distribution pattern of
HNE adducts in BDL group rats was diffuse throughout
the liver parenchyma, with strong staining for diffuse cy-
tosolic deposits in hepatocytes and in epithelial cells from
bile ducts and ductules. Staining for HNE adducts was far
less intense in liver samples from BDL  UDCA group
rats (Fig. 7C).
Protection by UDCA Against the Evolution of a
Population of Damaged Hepatocytes in Secondary
Biliary Cirrhosis. To assess whether the antioxidant ef-
fects of UDCA treatment led to protection against cell
injury, we investigated the hepatocyte populations in an-
imals with secondary biliary cirrhosis. First, the effects of
chronic cholestasis and UDCA treatment on hepatocyte
size were studied by flow cytometry, using forward-angle
Fig. 4. Effects of chronic cholestasis and UDCA treatment on mito-
chondrial glutathione redox status. (A) GSH and (B) GSSG levels in liver
mitochondria from control group rats, BDL group rats, and UDCA  BDL
group rats after 21 and 28 days of chronic cholestasis. Five to eight
experiments were performed in each case. Statistical differences were
assessed using ANOVA and Tukey–Kramer multicomparison tests.
Fig. 5. Effects of chronic cholestasis and UDCA treatment on gluta-
thione synthesis in hepatocytes. The rates of GSH synthesis were mea-
sured in isolated hepatocytes from control group rats, BDL group rats,
and UDCA  BDL group rats after 21 days of chronic cholestasis. Rats
were subjected to 48 hours of fasting before isolation of hepatocytes.
Hepatocytes were incubated with one of two sets of glutathione precur-
sors: (A) 5 mM Gln, 2 mM Gly, 1 mM Ser, and 0.5 mM Met; or (B) 5 mM
Gln and 2 mM Gly plus 0.5 mM NAC.
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scattering. Figure 8 shows representative assays of hepa-
tocytes isolated from sham, BDL, and BDL  UDCA
group rats. Two distinct populations were found in hepa-
tocytes from BDL group rats: one of normal-size cells
(similar to hepatocytes from sham-operated rats) and an-
other of smaller cells. The same two populations were
found in hepatocytes fromBDLUDCAgroup rats, but
the proportion of smaller cells was much lower (P 
.0119) in this group than in the BDL group (Fig. 8).
Mitochondrial cardiolipin content in smaller hepato-
cytes was approximately three times lower than in nor-
mal-size hepatocytes from BDL group rats (167  23
arbitrary fluorescence units [afu] vs. 64 13 afu; n 3;
P  .01) and five times lower than in hepatocytes from
control rats (302 46 afu vs. 64 13 afu; n 3–4; P
.01). Mitochondrial membrane potential in smaller hepa-
tocytes was three times lower than in normal-size hepato-
cytes from BDL group rats (75 20 afu vs. 22 6.1 afu;
n  3; P  .05) and six times lower than in hepatocytes
from control rats (148  25 afu vs. 22  6.1 afu; n 
3–4; P  .01).
Annexin V was used to detect translocation of phos-
phatidylserine to the outer leaflet of the plasma mem-
brane; such translocation is a marker of the apoptotic
process in isolated hepatocytes.We found that at least half
of the population (58%  8%; n  3) of small hepato-
cytes from BDL group rats exhibited high levels of fluo-
rescence with annexin V (Fig. 9); this elevated
fluorescence is characteristic of apoptotic hepatocytes.
The lack of propidium iodide fluorescence confirmed that
these hepatocytes still were viable. The marked decreases
in cardiolipin levels and mitochondrial membrane poten-
Fig. 6. Effects of chronic cholestasis and UDCA treatment on expres-
sion of -GCS and -cystathionase in rat liver samples. mRNA levels
were measured using real-time reverse-transcription PCR. Protein expres-
sion of the heavy subunit of -GCS was measured using Western blot
analysis. Gene expression of the -GCS (A) heavy and (C) light subunits
and of (D) -cystathionase was lower in BDL group rats than in control
group rats (P  .01, P  .001, and P  .001, respectively). Treatment
with UDCA restored expression of the -GCS heavy subunit at the (A)
mRNA and (B) protein levels (P  .05 for BDL group rats vs. BDL 
UDCA group rats) and partially restored gene expression of the -GCS
light subunit (P  .05 for BDL group rats vs. BDL  UDCA group rats;
P  .01 for BDL  UDCA group rats vs. control group rats). Real-time
quantitation of -GCS heavy subunit, -GCS light subunit, and cysta-
thionase mRNA expression relative to GAPDH mRNA expression was
performed. PCR data are shown as mean values  standard deviations
for each gene relative to an arbitrary value of 1, which was assigned to
expression levels in control group animals. Densitometry data from
Western blots are presented as mean values  standard deviations and
are shown together with representative experimental images in (B). Three
to five different experiments were performed in each case.
Fig. 7. Immunohistochemical staining for HNE-
protein adducts in secondary biliary cirrhosis: pro-
tective effects of UDCA treatment. HNE-protein
adducts were measured as an index of oxidative
damage to proteins in (A) control group, (B) BDL
group, and (C) UDCA  BDL group rats. Each
image is representative of three different experi-
ments. Original magnification 200.
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tial that were observed in small hepatocytes from BDL
group rats appeared to render these cells susceptible to
apoptosis. Thus, we can conclude that the population of
small hepatocytes was formed by the damaged and pri-
marily apoptotic hepatocytes that are present in the liver
during chronic cholestasis.
UDCA treatment almost completely prevented the de-
velopment of a cell population formed by damaged hepa-
tocytes in animals with chronic cholestasis (Fig. 8). Two
distinct populations were found in hepatocytes fromBDL
 UDCA group rats, but the proportion of hepatocytes
with decreased cardiolipin content, decreased membrane
potential, and small size was much lower than the corre-
sponding proportion in BDL group rats. The distribution
of hepatocytes was as follows: 54%  13% normal-size
cells and 30% 8% small cells in BDL group rats, com-
pared with 78% 9% normal-size cells and 12% 3%
small cells in BDL UDCA group rats (P  .0119).
Prevention by UDCA of Cholestasis-Induced De-
creases in Mitochondrial Cardiolipin Levels and
Membrane Potential. Oxidative stress lowers cardio-
lipin levels and membrane potential in mitochondria.37,38
Consequently, we investigated these parameters using
flow cytometry in hepatocytes isolated from rats subjected
to chronic cholestasis and treatment with UDCA. We
found that cardiolipin levels in normal-size hepatocytes
from BDL group rats were significantly lower (P  .05)
than cardiolipin levels in hepatocytes from sham-operated
rats (Fig. 10A). Treatment with UDCA completely pre-
vented the decrease in mitochondrial cardiolipin levels
that would have been induced by chronic cholestasis (P
.05 for the comparison with BDL group rats).
Mitochondrial membrane potential was significantly
lower in normal-size hepatocytes from BDL group rats
than in hepatocytes from sham-operated rats (P  .05).
UDCA treatment completely restored normal membrane
potential (P .01 for comparison with BDL group rats;
Fig. 10B).
Discussion
Cholestasis-Induced Oxidative Stress Caused by In-
creased Mitochondrial Production of ROS and by
Increased Glutathione Oxidation. Chronic cholestasis
induced by BDL in rats is associated with oxidative stress,
as evidenced by increased lipid peroxide levels and low
antioxidant enzyme activity in the liver.39 Liver mito-
chondria also exhibit increased levels of thiobarbituric
Fig. 8. Representative experiments showing hepatocyte populations in secondary biliary cirrhosis and the protective effects of UDCA treatment.
Hepatocyte size was measured by flow cytometry using forward-angle scattering. Hepatocytes were isolated from (A) control group, (B) BDL group,
and (C) UDCA  BDL group rats. Two separate populations were found in hepatocytes from BDL group rats, according to size. The percentage of
hepatocytes with smaller size and less morphologic complexity was higher in BDL group rats than in control group rats. UDCA treatment significantly
prevented the cholestasis-induced change in hepatocyte size.
Fig. 9. Representative experiment showing detection of phosphatidyl-
serine exposure in small hepatocytes from BDL group rats. Phosphati-
dylserine exposure was measured by flow cytometry, using annexin V as
a fluorochrome.
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acid–reactive substances and diminished levels of GSH
during experimental cholestasis.40 In the current study,
we found several indicators of oxidative stress, such as
increased GSSG levels and increased levels of HNE-pro-
tein adducts, in BDL group rats.
A noteworthy increase in mitochondrial ROS produc-
tion occurs during chronic cholestasis in rats. It has been
reported that hydrophobic acids enhance ROS produc-
tion in liver mitochondria from control rats.5,10 Nonethe-
less, to our knowledge, the current study is the first to
assess the rate of peroxide production in liver mitochon-
dria from rats with cirrhosis under State 4 conditions
using physiologic substrates linked to complexes I and II.
These conditions are much more similar to in vivo condi-
tions in the livers of rats with cirrhosis.
Our data support the hypothesis of Sokol et al.,12 who
proposed that bile acids accelerate superoxide generation
at complex I and ubisemiquinone, overwhelming the en-
dogenous mitochondrial antioxidant defense. In another
study, Sokol et al.5 reported that hydrophobic bile acids
enhanced the generation of hydroperoxides in isolated
mitochondria from control rats. The results of the current
study indicate that chronic cholestasis leads to increased
peroxide production via mitochondrial complexes I and
III, as enhancement was noted with both pyruvate/malate
and succinate substrates. The observed threefold increase
in the rate of mitochondrial peroxide production suggests
that the contribution of mitochondria to oxidative dam-
age in biliary cirrhosis may have been underestimated.
The high level of mitochondrial production of ROS also
accounts for the oxidative damage and glutathione oxida-
tion observed in the liver (particularly in mitochondria)
during biliary cirrhosis and may be responsible for mito-
chondrial impairment.41 These effects are exacerbated in
chronic cholestasis, because peroxide production via mi-
tochondrial complexes increases as biliary cirrhosis
progresses.
Under physiologic conditions, cysteine availability is
the limiting factor for GSH synthesis in the liver,36 par-
ticularly in cases of cirrhosis, in which the transulfuration
pathway appears to be critically impaired. In fact, methi-
onine adenosyltransferse and cystathionine -synthase
exhibit decreased activity and mRNA levels in cirrho-
sis.42–44 We now report that -cystathionase mRNA lev-
els are low in chronic cholestasis. Accordingly, in rats with
cirrhosis, synthesis of GSH from methionine, which in-
volves the transulfuration pathway, is diminished. Fur-
thermore, the rate of synthesis of GSH from NAC was
diminished in hepatocytes from BDL group rats; this
finding was in agreement with the finding of decreased
-GCS expression.
Cardiolipin may modulate apoptotic processes by in-
hibiting MPT. In fact, it provides an increased pool of
negative ions that nonspecifically bind Ca2, thereby pre-
venting it from binding to protein sites that induce the
opening of mitochondrial pores.45 Lieser et al.46 found
that mitochondrial cardiolipin content increased 10 days
after BDL and thus protected against cell death by in-
creasing the threshold for MPT. Nonetheless, this adap-
tive mechanism appears to function only during the first
days of cholestasis, as we observed a decrease inmitochon-
drial cardiolipin content after 21 days of chronic cholesta-
sis. This decrease in cardiolipin levels may be due to
increased mitochondrial peroxide production induced by
chronic cholestasis, as ROS lead to oxidative cardiolipin
damage and decreased mitochondrial cardiolipin con-
tent.38
Fig. 10. Representative histograms showing (A) mitochondrial cardi-
olipin content and (B) mitochondrial membrane potential in secondary
biliary cirrhosis, along with the protective effects of UDCA treatment.
Mitochondrial cardiolipin content was measured in isolated rat hepato-
cytes by flow cytometry, using nonylacridine orange as a fluorochrome.
Mitochondrial membrane potential was determined by flow cytometry in
isolated hepatocytes using rhodamine 123 at 525 nm fluorescence
emission. Hepatocytes were isolated from control group (C), BDL group,
and BDL  UDCA group rats after 21 days of chronic cholestasis.
Nonylacridine orange and rhodamine 123 fluorescence levels were sig-
nificantly lower (P .05) in BDL group rats compared with control group
rats and BDL  UDCA group rats. No significant difference was found
between control group rats and BDL  UDCA group rats. Insets show
plots for three to four experiments.
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We also found two different populations of hepato-
cytes in rats with cirrhosis: one of these populations ex-
hibited cell damage that was characterized by dramatic
losses in mitochondrial cardiolipin content and mem-
brane potential. We postulate that increased mitochon-
drial ROS production and decreased cardiolipin content
create a vicious cycle, because these two effects potentiate
each other. In fact, diminished mitochondrial cardiolipin
content leads to decreased mitochondrial complex I activ-
ity38 and thus may account for the decreased mitochon-
drial membrane potential and increased leakage of ROS
through the mitochondrial electron transport chain in
chronic cholestasis.
UDCA Treatment Restores GSH Synthesis From
Cysteine and Diminishes Oxidative Stress in Chronic
Cholestasis. UDCA is a hydrophilic bile acid that is
increasingly used to treat various cholestatic disorders. It
normally is present in human bile, albeit at a low concen-
tration, accounting for only approximately 3% of total
bile acid. To date, UDCA has been used widely to treat
PBC, for which it is the only drug approved by the United
States Food and Drug Administration. Although UDCA
represents the current and primary treatment for choles-
tatic disorders, the mechanisms underlying its effects are
in the process of being elucidated.
It should be noted that UDCA treatment significantly
increased expression of -GCS, but not expression of
-cystathionase. Consequently, UDCA increased the rate
of GSH synthesis when cysteine availability was not a
limiting factor. This finding is in agreement with previous
in vitro data indicating that UDCA could induce -GCS
expression in hepatocytes that were experiencing chemical
oxidative stress.24 Furthermore, our results suggest that
cotreatment with NAC, which would prevent limitations
in cysteine availability due to low -cystathionase activity
during biliary cirrhosis, should be recommended.
The positive effect on -GCS expression contributes to
the protective effects of UDCA against oxidative stress in
liver homogenates as well as in mitochondria, as evi-
denced by diminished levels of GSSG and HNE-protein
adducts. The antioxidant defense mediated by GSH is
enhanced by UDCA treatment in secondary biliary cir-
rhosis; this defense prevents the development of cell in-
jury during chronic cholestasis. In fact, a population of
damaged and primarily apoptotic hepatocytes, which exhib-
ited dramatic losses in mitochondrial cardiolipin content
andmembrane potential, as well as phosphatidylserine expo-
sure, evolved during chronic cholestasis. UDCA treatment
prevented the growth of this cell population.
It has been established that oxidative stress is an early
event in apoptosis47 and that mitochondrial oxidative
stress renders hepatocytes much more susceptible to eth-
anol-induced apoptosis.28 Therefore, the beneficial effects
of UDCA against chronic cholestasis appear to be medi-
ated, at least in part, by protection against mitochondrial
oxidative stress. Because oxidative stress may lead to oxi-
dation and depletion of cardiolipin, the inhibitory effects
of UDCA against mitochondrial peroxide production
and oxidation of glutathione may be responsible for the
subsequently observed maintenance of cardiolipin levels.
This effect also would provide protection against cell
death.
The effect of UDCA on the progression of liver fibrosis
in PBC recently was defined.48 According to Corpechot et
al.,48 UDCA therapy significantly delays the progression
of liver fibrosis in early-stage PBC (i.e., PBC without ex-
tensive fibrosis). Although UDCA protects against oxida-
tive stress, we observed no significant difference in terms
of degree of fibrosis between BDL group rats and BDL
UDCA group rats in ourmodel of established cirrhosis, in
which all compensatory actions had proved insufficient
(results not shown). Thus, although UDCA is able to
protect against mitochondrial and overall cellular oxida-
tive stress, additional treatment should be recommended
to effectively reduce the rate of fibrogenesis during the late
stages of cirrhosis.
In conclusion, we have demonstrated that UDCA
treatment up-regulates -GCS expression and conse-
quently increases the rate of GSH synthesis in secondary
biliary cirrhosis. UDCA treatment also was found to pre-
vent the marked increases in mitochondrial peroxide pro-
duction and oxidative protein damage that normally
occur during chronic cholestasis. These antioxidant ef-
fects led to the prevention of cardiolipin depletion and
cellular injury in secondary biliary cirrhosis.
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